IP Library › Granted Patent US 12,318,438
Granted Patent B2
US 12,318,438 · App. 17/812,777 · Granted Jun 3, 2025

Immunogenic compositions for use in pneumococcal vaccines

Inventors: David Cooper (Monroe, NY); Kathrin Ute Jansen (New York, NY); Michael William Pride (Staten Island, NY)
Assignee: Pfizer Inc.
A61K39/092A61K39/39A61K2039/55505A61K2039/6037A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,438
App. No.
17/812,777
Granted
Jun 3, 2025
Kind
B2
Abstract

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae , in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

Claims (25)

1. A method for immunizing a human subject against an infection caused by S. pneumoniae serotype 18A, 18B and/or 18F in a human subject, said method comprising administering to said human subject an immunogenic composition comprising:

(a) at least one glycoconjugate from S. pneumoniae serotype 18C capsular polysaccharide;

(b) glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F and 23F capsular polysaccharides; and

(c) at least one glycoconjugate from S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F and 33F;

wherein said immunogenic composition does not comprise capsular saccharide from S. pneumoniae serotypes 18A, 18B and 18F; and

wherein said human subject has previously received a pneumococcal polysaccharide vaccine.

2. The method of claim 1 , wherein said immunogenic composition further comprises at least one glycoconjugate selected from the group consisting of S. pneumoniae serotypes 2, 9N, 15C, 17F and 20.

3. The method of claim 1 , wherein said immunogenic composition comprises a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25-valent pneumococcal conjugate composition.

4. The method of claim 1 , wherein said glycoconjugates are individually conjugated to CRM197, tetanus toxoid (TT), Haemophilus influenzae protein D (PD) or Diphtheria toxin (DT).

5. The method of claim 1 , wherein said subject is a human less than 1 year of age.

6. The method of claim 1 , wherein said subject is a human less than 2 years of age.

7. The method of claim 1 , wherein said subject is a human adult 18 years of age or older.

8. The method of claim 1 , wherein said subject is a human adult 50 years of age or older.

9. The method of claim 1 , wherein said immunogenic composition is administered in a single dose vaccination schedule.

10. The method of claim 1 , wherein said immunogenic composition is administered in a multiple dose vaccination schedule.

11. The method of claim 10 , wherein said multiple dose vaccination schedule comprises a series of 2 doses, 3 doses or 4 doses of the immunogenic composition.

12. The method of claim 11 , wherein the series of 4 doses of the immunogenic composition is administered at 2, 4, 6, and 12-15 months of age.

13. The method of claim 1 , wherein said immunogenic composition comprises at least one buffer, at least one salt, and at least one surfactant.

14. The method of claim 13 , wherein said buffer is selected from phosphate, succinate, histidine and citrate.

15. The method of claim 13 , wherein said salt is selected from magnesium chloride, potassium chloride, and sodium chloride.

16. The method of claim 13 , wherein said surfactant is selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, polysorbate 85, polyethylene glycol nonylphenyl ether, t-octylphenoxypolyethoxyethanol, oxtoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate (PEG-15, Solutol H 15), polyoxyethylene-35-ricinoleate, soy lecithin and a poloxamer.

17. The method of claim 1 , wherein said immunogenic composition comprises at least one adjuvant.

18. The method of claim 17 , wherein said adjuvant is selected from aluminum phosphate, aluminum sulfate, and aluminum hydroxide.

19. The method of claim 1 , wherein said immunogenic composition is administered at a volume of about 0.5 mL.

20. The method of claim 1 , wherein said human subject has previously received said pneumococcal polysaccharide vaccine at least 5 years before being administered said immunogenic composition.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →
Continuity (3)
Continuation 16478265
Provisional Application 62448485 · Jan 20, 2017
Related Publication 20230190907A1 · Jun 22, 2023
References Cited (113)
US 4709017A · Collier et al. · 1987 [cited by applicant]
US 4950740A · Greenfield et al. · 1990 [cited by applicant]
US 5614382A · Metcalf · 1997 [cited by applicant]
US 5843711A · Collier et al. · 1998 [cited by applicant]
US 5917017A · Collier et al. · 1999 [cited by applicant]
US 6194388B1 · Krieg et al. · 2001 [cited by applicant]
US 6207646B1 · Krieg et al. · 2001 [cited by applicant]
US 6214806B1 · Krieg et al. · 2001 [cited by applicant]
US 6218371B1 · Krieg et al. · 2001 [cited by applicant]
US 6239116B1 · Krieg et al. · 2001 [cited by applicant]
US 6339068B1 · Krieg et al. · 2002 [cited by applicant]
US 6455673B1 · Collier · 2002 [cited by applicant]
US 10105412B2 · Gierahn et al. · 2018 [cited by applicant]
US 11413344B2 · Cooper et al. · 2022 [cited by applicant]
US 20060228380A1 · Hausdorff et al. · 2006 [cited by applicant]
US 20060228381A1 · Bahler et al. · 2006 [cited by applicant]
US 20070184071A1 · Hausdorff et al. · 2007 [cited by applicant]
US 20070184072A1 · Hausdorff et al. · 2007 [cited by applicant]
US 20070231340A1 · Hausdorff et al. · 2007 [cited by applicant]
US 20080102498A1 · Bahler et al. · 2008 [cited by applicant]
US 20080286838A1 · Yuan et al. · 2008 [cited by applicant]
US 20110020386A1 · Gierahn et al. · 2011 [cited by applicant]
US 20150202309A1 · Emini et al. · 2015 [cited by applicant]
US 20160324949A1 · Han et al. · 2016 [cited by applicant]
US 20170157241A1 · Li et al. · 2017 [cited by applicant]
US 20180000922A1 · Cooper et al. · 2018 [cited by applicant]
CA 2004810 · 1990 [cited by applicant]
CN 102068690A · 2011 [cited by applicant]
CN 103495161A · 2014 [cited by applicant]
EP 0378881B1 · 1993 [cited by applicant]
EP 0427347B1 · 1995 [cited by applicant]
EP 0471177B1 · 1995 [cited by applicant]
EP 0594610B1 · 1998 [cited by applicant]
EP 0735898B1 · 1999 [cited by applicant]
EP 0761231B1 · 2000 [cited by applicant]
EP 0689454B2 · 2005 [cited by applicant]
WO 9003184A1 · 1990 [cited by applicant]
WO 9101146A1 · 1991 [cited by applicant]
WO 9315760A1 · 1993 [cited by applicant]
WO 9317712A2 · 1993 [cited by applicant]
WO 9403208A1 · 1994 [cited by applicant]
WO 9508348A1 · 1995 [cited by applicant]
WO 9602555A1 · 1996 [cited by applicant]
WO 9611711A1 · 1996 [cited by applicant]
WO 9701640A2 · 1997 [cited by applicant]
WO 9818810A1 · 1998 [cited by applicant]
WO 9836772A1 · 1998 [cited by applicant]
WO 9842721A1 · 1998 [cited by applicant]
WO 9857659A1 · 1998 [cited by applicant]
WO 9858668A2 · 1998 [cited by applicant]
WO 9911241A1 · 1999 [cited by applicant]
WO 9944636A2 · 1999 [cited by applicant]
WO 9952549A1 · 1999 [cited by applicant]
WO 0007621A2 · 2000 [cited by applicant]
WO 0023105A2 · 2000 [cited by applicant]
WO 0037105A2 · 2000 [cited by applicant]
WO 0039299A2 · 2000 [cited by applicant]
WO 0041720A1 · 2000 [cited by applicant]
WO 0048630A1 · 2000 [cited by applicant]
WO 0056357A2 · 2000 [cited by applicant]
WO 0056358A2 · 2000 [cited by applicant]
WO 0061761A2 · 2000 [cited by applicant]
WO 0062800A2 · 2000 [cited by applicant]
WO 0121152A1 · 2001 [cited by applicant]
WO 0121207A2 · 2001 [cited by applicant]
WO 0172337A1 · 2001 [cited by applicant]
WO 0198334A2 · 2001 [cited by applicant]
WO 02091998A2 · 2002 [cited by applicant]
WO 03024480A2 · 2003 [cited by applicant]
WO 03054007A2 · 2003 [cited by applicant]
WO 2004081515A2 · 2004 [cited by applicant]
WO 2004083251A2 · 2004 [cited by applicant]
WO 2005033148A1 · 2005 [cited by applicant]
WO 2006032499A1 · 2006 [cited by applicant]
WO 2006110352A2 · 2006 [cited by applicant]
WO 2006110381A1 · 2006 [cited by applicant]
WO 2006134423A2 · 2006 [cited by applicant]
WO 2007026190A2 · 2007 [cited by applicant]
WO 2007071707A2 · 2007 [cited by applicant]
WO 2007116028A2 · 2007 [cited by applicant]
WO 2008079653A1 · 2008 [cited by applicant]
WO 2008079732A2 · 2008 [cited by applicant]
WO 2008118752A2 · 2008 [cited by applicant]
WO 2008143709A2 · 2008 [cited by applicant]
WO 2009000826A1 · 2008 [cited by applicant]
WO 2010109324A1 · 2010 [cited by applicant]
WO 2010125480A1 · 2010 [cited by applicant]
WO 2014027302A1 · 2014 [cited by applicant]
WO 2014097099A2 · 2014 [cited by applicant]
WO 2016113644A1 · 2016 [cited by applicant]
U.S. Appl. No. 16/478,265, filed Jul. 16, 2019. [cited by applicant]
Baraldo et al, “N19 Polyepitope as a Carrier for Enhanced Immunogenicity and Protective Efficacy of Meningococcal Conjugate Vaccines”, Infection and Immunity 72(8):4884-4887 (2004). [cited by applicant]
Bethell et al, “A Novel Method of Activation of Cross-linked Agaroses with 1,1′-Carbonyldiimidazole Which Gives a Matrix for Affinity Chromatography Devoid of Additional Charged Groups”, The Journal of Biological Chemis… [cited by applicant]
ClinicalTrials.gov, “Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults”, Pfizer, NCT00427895 Study Details. First Posted Jan. 29, 2007. (accessed Sep… [cited by applicant]
ClinicalTrials.gov, “Study Evaluating The Safety, Tolerability and Immunogenicity of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)”, Pfizer, NCT00546572 Study Details. First posted Oct. 19, 2007. (accessed Sep. 21… [cited by applicant]
Crooke, et al., “Progress in Antisense Oligonucleotide Therapeutics”, Annu. Rev. Pharmacol. Toxicol. 36:107-129 (1996). [cited by applicant]
Douglas et al, “Exotoxin A of [cited by applicant]
Falugi et al, “Rationally designed strings of promiscuous CD4+ T cell epitopes provide help to Haemophilus Influenzae type b oligosaccharide: a model for new conjugate vaccines”, Eur. J. Immunol. 31:3816-3824 (2001). [cited by applicant]
Hearn et al, “Application of 1, 1′-Carbonyldiimidazole-Activated Matrices for the Purification of Proteins: III. The Use of 1, 1′-Carbonyldiimidazole-Activated Agaroses in the Biospecific Affinity Chromatographic Isolat… [cited by applicant]
Hestrin et al, “The Reaction of Acetylcholine and other Carboxylic Acid Derivatives With Hydroxylamine, and Its Analytical Application”, J. Biol. Chem. 180:249-261 (1949). [cited by applicant]
Hsu et al, “Effect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitidis”, The New England Journal of Medicine 360:244-256 (2009). [cited by applicant]
Hu, et al., “Approach to Validating an Opsonophagocytic Assay for [cited by applicant]
Hunziker, et al., “Nucleic Acid Analogues: Synthesis and Properties”, Mod. Synth. Methods 7:331-417 (1995). [cited by applicant]
Jones et al, “Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture”, Journal of Pharmaceutical and Biomedical Analysi… [cited by applicant]
Kuo et al, “Characterization of a Recombinant Pneumolysin n and Its Use as a Protein Carrier for Pneumococcal Type 18C Conjugate Vaccines”, Infection and Immunity 63(7):2706-2713 (1995). [cited by applicant]
Lemercinier et al, “Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production”, Carbohydrate Research 296(1-4):83-96 (1996). [cited by applicant]
Pride et al, “Validation of an Immunodiagnostic Assay for Detection of 13 [cited by applicant]
Sjölander et al, “ISCOMs: an adjuvant with multiple functions”, J. Leukoc. Biol. 64:713-723 (1998). [cited by applicant]
Tanmoy et al, “PCR-Based Serotyping of [cited by applicant]
Uchida et al, “Mutation in the Structural Gene for Diphtheria Toxin Carried by Temperate Phage Beta”, Nature New Biology 233:8-11 (1971). [cited by applicant]
Uchida et al, “Diphtheria Toxin and Related Proteins: I. Isolation and Properties of Mutant Proteins Serologically Related to Diphtheria Toxin”, The Journal of Biological Chemistry 248(11):3838-3844 (1973). [cited by applicant]
Uhlmann et al, “Antisense Oligonucleotides: A New Therapeutic Principle”, Chemical Reviews 90(4):543-584 (1990). [cited by applicant]
Domenech, M. et al., “In vitro biofilm formation by [cited by applicant]